Clinical Trials Browser

Phase 2 × INDUSTRY × bemcentinib × Clear all

NCT03184571 2025-09-25

Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Phase 2 Completed

99 enrolled 20 charts

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

NCT03184558 2021-11-09

Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC

Phase 2 Terminated

29 enrolled 10 charts

Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms